Less than 14 months after stopping its GALACTIC-1 study for certain patients due to safety concerns, Galecto has hit its enrollment target for the Phase 2b trial — now under a revised protocol — testing its investigational inhaled therapy GB0139 for idiopathic pulmonary fibrosis (IPF). Galecto had resumed trial…
Are there sounds you associate with your happy place? Perhaps it’s a smell. For me, it’s the sound of a metal whisk in a metal bowl, the rhythm of a chef’s knife prepping ingredients, the aroma of a mirepoix as it begins to sweat. Food is my love language. I’ve…
A new multiphase educational collaboration seeks to slash the time it takes for many people to receive a diagnosis of interstitial lung disease (ILD), including pulmonary fibrosis (PF). The Three Lakes Foundation and the American College of Chest Physicians (CHEST) will work together to heighten disease awareness among healthcare…
The first patient has been enrolled in a U.S. clinical trial evaluating the efficacy and safety of a new artificial intelligence-based app, called Almee, that’s designed to treat anxiety in people with idiopathic pulmonary fibrosis (IPF). Almee, developed by Vicore Pharma, is an experimental digital therapy that delivers…
Although the past two years have been traumatic and isolating, I believe some good things have emerged from the COVID-19 pandemic. It can be hard to reframe our thoughts to focus on the positive, but if you’re like me, these years have allowed for many moments of deep self-reflection.
Organizers say that just a few tickets are still available for this year’s rendition of the Broadway Belts for PFF! fundraiser, benefitting the Pulmonary Fibrosis Foundation (PFF). The annual event, slated for April 29 at the Edison Ballroom in New York City, again will bring together an array of…
Face mask: check. COVID-19 vaccine card: check. Extra mask: check. Electronic vaccination card: check. Anxiety: check. More than 25 months after the start of the pandemic, my wife, Susan, and I returned to the theater. The National Theatre, located in the heart of Washington, D.C., has always been…
“Wow, that is a rare lung disease. I have heard of lymphocytic interstitial pneumonia [LIP], but I have never known or treated anyone with this disease. Your case will be interesting.” That’s what my cardiologist said when I went for my first consultation regarding my hospital stay for symptoms of…
Enrollment is now complete in ZEPHYRUS-1, a Phase 3 trial of pamrevlumab, an investigational treatment for idiopathic pulmonary fibrosis (IPF), the therapy’s developer, FibroGen, announced. The randomized, placebo-controlled trial (NCT03955146) now includes 356 IPF patients across 144 sites worldwide. It aims to evaluate the safety and efficacy…
Bridge Biotherapeutics has entered an exclusive in-licensing agreement with Shaperon to develop BBT-209, an investigational therapy for idiopathic pulmonary fibrosis (IPF). “We hope that BBT-209 will become a breakthrough therapy for patients with IPF, who are currently lacking treatment options,” Seung-Yong Seong, MD, PhD and Myung-Sea Lee, MD,…
Get regular updates to your inbox.
